Publications/ References
1) R. Hellweg, U.E. Lang, M. Nagel, A. Baumgartner (2002) Subchronic treatment with lithium increases
nerve growth factor content in distinct brain regions of adult rats. Molecular Psychiatry 7: 604-8.
2) U.E. Lang, J. Gallinat, S. Kuhn, R. Hellweg (2002) Nerve Growth Factor and Smoking Cessation. Am J
Psychiatry 159: 674-675.
3) S. Waldegger, U. Lang, T. Herzer, H. Suessbrich, K. Binder, A. Lepple-Wienhues, U. Nagl, M.
Paulmichl, H.B.G. Franz, L. Kiesl, F. Lang, A. E. Busch (1996) Inhibition of the MinK protein induced K
channels in Xenopus oocytes by estrogens. Naunyn Schmiedeberg´s Arch Pharmakol 354: 698-702.
4) U.E. Lang, Piche, E., Juenger, M., Schlattmann, P., Jockers-Scherübl, M.C., Hellweg, R (2002) Nerve
growth factor serum levels are not elevated in patients with atopic dermatitis. Dermatology a n d
Psychosomatics 3: 30-33.
5) C. Gericke, U.E. Lang, T. Steckler, T. Schulz, R. Hellweg (2003) Nerve Growth Factor content and
ChAT activity in different brain regions after excitotoxic lesion of the nucleus magnocellularis in old and
young rats. J Neural Transmission 110: 627-39.
6) J. Gallinat, G. Stotz-Ingenlath, U.E. Lang, U. Hegerl (2003). Panic attacks, spike-wave activity, and
limbic dysfunction. Pharmacopsychiatry 36: 123-6.
7) S. M. Gold, S. Hartmann, M. Mladek, U.E. Lang, R. Hellweg, R. Reer, M. K. Braumann, K.-H. Schulz,
C. Heesen (2003) Basal plasma levels and reactivity of nerve growth factor (NGF) and brain-derived
neurotrophic factor (BDNF) to standardized acute exercise in multiple sclerosis and controls. J
Neuroimmunol 138: 99-105.
8) U.E. Lang, J. Gallinat, H. Danker-Hopfe, M. Bajbouj, R. Hellweg (2003) Nerve Growth Factor serum
concentrations in healthy volunteers: physiological variance and stability. Neurosci Lett 344: 13-6.
9) U.E. Lang, F. Lang, K. Richter, V. Vallon, H.-P. Lipp, J. Schnermann, D. P. Wolfer (2003) Emotional
instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav Brain Research 145:
179-188.
10) M. Bajbouj, J. Gallinat, U.E. Lang, L. Niehaus (2003) Motorcortical excitability after electroconvulsive
therapy in patients with major depressive disorder. Suppl Clin Neurophysiol 56: 433-40.
11) M. Jockers-Scherübl, U. Matthies, H. Danker-Hopfe, U.E. Lang, R. Hellweg (2003). Chronic cannabis
abuse raises nerve growth factor concentrations in drug-naive schizophrenic patients. J
Psychopharmacology 17: 439-45.
12) S. von Richthofen*, U.E. Lang*, R. Hellweg (2003) Effects of stress on NGF content in rat brain. Brain
Research 987: 207-213.
13) M. Bajbouj, J. Gallinat; L. Niehaus, U.E. Lang, S. Röricht, B.-U. Meyer (2004) Abnormalities of
inhibitory neuronal mechanisms in the motor cortex of patients with schizophrenia. Pharmacopsychiatry
37: 74-80.
14) U.E. Lang, M. Mühlbacher, H. Hesselink, W. Zajaczkowski, W. Danysz, H. Danker-Hopfe, R. Hellweg
(2004) No nerve growth factor response to treatment with memantine in adult rats. J Neural Transmission
111: 181-90.
15) U.E. Lang, D. Anders, H. Danker-Hopfe, R. Hellweg (2004) Measurement of Nerve Growth Factor
serum concentration in a psychologically stressful situation. Stress 7: 39-42.
16) S. Chourbaji, R. Hellweg, D. Brandis, B. Zörner, C. Zacher, U.E. Lang, F. A. Henn, H. Hörtnagl, P. Gass
(2004) Mice with reduced BDNF expression show decreased choline acetyltransferase activity, but
regular brain monoamine levels and unaltered emotional behavior. Brain Res Mol Brain Res 121: 28-36.
17) U.E. Lang, R. Hellweg, J. Gallinat (2004) BDNF serum concentrations in healthy humans are associated
with depression-related personality traits. Neuropsychopharmacology 29: 795-8.
18) K.-H. Schulz, S.M. Gold, J. Witte, K. Bartsch, U.E. Lang, R. Hellweg, R. Reer, K.-M. Braumann, C.
Heesen (2004) Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality
of life and coordinative function in multiple sclerosis. Neurol Sci 225: 11-8.
19) U.E. Lang, M.C. Jockers-Scherübl, R. Hellweg (2004) Neurotrophins in psychiatric disorders. State of
the art: implications and limitations. J Neural Transmission 111: 387-411.
20) U.E. Lang, M. Bajbouj , C. Wernicke, H. Rommelspacher , H. Danker-Hopfe, J. Gallinat (2004) No
association of a functional polymorphism in the serotonin transporter gene promoter and anxiety-related
personality traits. Neuropsychobiology 49:182-4.
21) M.C. Jockers-Scherubl, H. Danker-Hopfe R. Mahlberg, F. Selig, J. Rentzsch, F. Schurer, U.E. Lang, R.
Hellweg (2004) Brain-derived neurotrophic factor serum concentrations are increased in drug-naive
schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371: 7983.
22) N. Jeck , S. Waldegger, A. Lampert, C. Boehmer, P. Waldegger, P.A. Lang, B. Wissinger, B. Friedrich,
T. Risler, R. Moehle, U.E. Lang, P. Zill, B. Bondy, E. Schaeffeler, S. Asante-Poku, H. Seyberth, M.
Schwab, F. Lang (2005) Activating Mutation of the Renal Epithelial Chloride Channel ClC-Kb
Predisposing to Hypertension. Hypertension 43: 1175-81.
23) J. Gallinat, D. Kunz, U.E. Lang, G. Juckel, R. Mahlberg, C. Wernicke, H. Rommelspacher, M.N. Smolka
(2005) Serotonergic effects of smoking are independent from the human serotonin transporter gene
promoter polymorphism: Evidence from auditory cortical stimulus processing. Pharmacopsychiatry 38:
158-160.
24) U.E. Lang, R. Hellweg, J. Gallinat (2005) Association of BDNF serum concentrations with central
serotonergic activity: Evidence from auditory signal processing. Neuropsychopharmacology 30: 1148-53.
25) U.E. Lang, R. Hellweg, P. Kalus, M. Bajbouj, K.P. Lenzen, T. Sander, D. Kunz, J. Gallinat (2005)
Association of a functional BDNF polymorphism and anxiety-related personality traits.
Psychopharmacology 180: 95-9.
26) N. Strutz-Seebohm, G. Seebohm, A. F. Mack, H.-J. Wagner, L. Just, T. Skutella, U.E. Lang, G. Henke,
M. Striegel, M. Hollmann, N. Rouach, R.A. Nicoll, J.A. McCormick, J. Wang, D. Pearce F. Lang (2005)
Regulation of GluR1 abundance in hippocampal neurons by serum- and glucocorticoid-inducible kinase
3. J Physiology 565: 381-90.
27) C. Sandu, R. Rexhepaj, F. Grahammer, J.A. McCormick, G. Henke, M. Palmada, S. Nammi, U. Lang, M.
Metzger, L. Just, T. Skutella, K. Dawson, J. Wang, D. Pearce, F. Lang (2005) Decreased intestinal glucose
transport in the sgk3-knockout mouse. Pflugers Arch 51: 437-44.
28) J. Gallinat, R. Hellweg, U.E. Lang (2005) Indicators of Central Serotonergic Activity: How 'Specific' is
Neurotransmission? Neuropsychopharmacology 30: 1586-1587.
29) J. Gallinat, A. Ströhle, MD, U.E. Lang, M. Bajbouj, P. Kalus, C. Montag, F. Seifert, C. Wernicke, H.
Rommelspacher, H. Rinneberg, F. Schubert (2006) Association of human hippocampal neurochemistry,
serotonin transporter genetic variation, and anxiety. Neuroimage 26: 123-31.
30) M. Bajbouj, A. Luborzewski, H. Danker-Hopfe, U.E. Lang (2005) Motor cortical excitability in
depressive patients after electroconvulsive therapy and repetitive transcranial magnetic stimulation. J
ECT 21: 243-5.
31) T. Müller, U.E. Lang, S. Muhlack, J. Welnic, R. Hellweg (2005) Impact of levodopa on reduced nerve
growth factor levels in Parkinson’s disease patients. Clinical Neuropharmacology 28: 238-240.
32) M. Bajbouj, U.E. Lang, P. Neu, I. Heuser (2005) Therapeutic brain stimulation and cortical excitability
in depressed patients. Am J Psychiatry 162:2192-3.
33) M. Bajbouj, E.L. Brakemeier, F. Schubert, U.E. Lang, P. Neu, C. Schindowski, H. Danker-Hopfe (2005)
Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex and cortical excitability
in patients with major depressive disorder. Exp Neurol 196: 332-8.
34) A. Frey, A. Lampert, S. Waldegger, N. Jeck, P. Waldegger, F. Artunc, G. Seebohm, U.E. Lang, S.
Kupka, M. Pfister, J. Hoppe, C. Gerloff, E. Schaeffeler, M. Schwab, F. Lang (2006) Influence of gain of
function epithelial chloride channel ClC-Kb mutation on hearing thresholds. Hear Res 214:68-75.
35) U.E. Lang, D.P. Wolfer, F. Grahammer, N. Strutz-Seebohm, G. Seebohm, H.-P. Lipp, J.A. McCormick,
R. Hellweg, K. Dawson, J. Wang, D. Pearce, F. Lang (2006) Reduced locomotion in the Serum and
Glucocorticoid inducible Kinase 3 knock out mouse. Behavioral Brain Research 167:75-86.
36) M. Bajbouj, U.E. Lang, E. Niehaus, F.E. Hellen, I. Heuser, P. Neu (2006) Effects of right unilateral
electroconvulsive therapy on motor cortical excitability in depressive patients. J Psychiatr Res 40(4):32237) M. Bajbouj, S.H. Lisanby, U.E. Lang, H. Danker-Hopfe, I. Heuser, P. Neu (2006) Evidence for Impaired
Cortical Inhibition in Patients with Unipolar Major Depression. Biol Psychiatry 59(5):395-400.
38) U.E. Lang, M. Bajbouj, J. Gallinat, R. Hellweg. Brain - derived neurotrophic factor serum concentrations
in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation.
Psychopharmacology 187: 56-9.
39) J. Kirchheiner, U.E. Lang, T. Stamm, T. Sander, J. Gallinat (2006) Association of CYP2D6 genotypes
and personality traits in psychiatric healthy individuals. J Clin Psychiatry 26: 440-2.
40) J. Gallinat*, U.E. Lang*, D. Kunz, P. Neu, N. Kassim, T. Kienast, F. Seifert, F. Schubert, M. Bajbouj
(2007) Association between cerebral glutamate and human behaviour: The sensation seeking personality
trait. Neuroimage 34: 671-8.
41) U.E. Lang, R. Hellweg (2006) Berufsunfähigkeit: Prävalenz und Rolle psychiatrischer Erkrankungen.
Versicherungsmedizin 58: 164-9.
42) M. Domula, D. Schulze, S.M. Tugtekin, W. Felber, U.E. Lang (2007) Cat eye syndrome associated with
schizophrenia. Pharmacopsychiatry 40: 38-9.
43) U.E. Lang, T. Sander, F.W. Lohoff, R. Hellweg, M. Bajbouj, J. Gallinat (2007) Association of the met66
allele of brain-derived neurotrophic factor (BDNF) with smoking. Psychopharmacology 190(4):433-9.
44) J. Gallinat, U.E. Lang, L.K. Jacobsen, M. Bajbouj, P. Kalus, D. vonHaebler, F. Seifert, F. Schubert
(2007) Abnormal hippocampal neurochemistry in smokers: Evidence from proton magnetic resonance
spectroscopy at 3 tesla. Clin Psychopharmacology 27: 80-4.
45) M. Bajbouj, J. Gallinat, U.E. Lang,; F. Hellen, J. Vesper; S.H. Lisanby, ; H. Danker-Hopfe,; P. Neu
(2007) Motor cortex excitability after vagus nerve stimulation in major depression. J Clin
Psychopharmacology 27:156-9.
46) A. Ziegenhorn, O. Schulte-Herbrüggen, H. Danker-Hopfe, M. Malbranc, H.-D. Hartung, D. Anders, U.E.
Lang, E. Steinhagen-Thiessen, R.T. Schaub, R. Hellweg (2006) Serum neurotrophins – a study on the
time course and influencing factors in a large old age sample. Neurobiol of Aging 28: 1436-45.
47) U.E. Lang, D. Stogowski, D. Schulze, M. Domula, E. Schmidt, W. Felber (2007) Charles Bonnet
Syndrome: Visual hallucinations due to vision loss disappeared during treatment with selective serotonin
reuptake inhibitors. J Psychopharmacology 21:553-5.
48) U.E. Lang, R. Hellweg, F Schubert, J. Gallinat (2007) Evidence for a role of BDNF on cortical integrity
in the living human brain. Biological Psychiatry 62: 530-5.
49) U.E. Lang, M. Willbring, R. von Golitschek, A. Schmeisser, K. Matschke, S. M. Tugtekin.
Clozapineinduced myocarditis after long term treatment: Case presentation and clinical perspectives. J
Psychopharmacology (in press)
50) U.E. Lang, M. Bajbouj, T. Sander, J. Gallinat (2007) Association of the functional catecholOmethyltransferase
VAL158MET polymorphism with the personality trait of sensation seeking.
Neuropsychopharmacology 32: 1950-5.
51) U.E. Lang*, R. Hellweg*, J. Gallinat, M. Bajbouj. Acute prefrontal cortex transcranial magnetic
stimulation in healthy volunteers: No effects on brain-derived neurotrophic factor (BDNF) concentrations
in serum. J Affective Disorder (in press)
52) U.E. Lang, I. Puls, D. Mueller, Nathalie Strutz-Seebohm, Juergen Gallinat. Molecular Mechanisms of
Schizophrenia. Cell Physiol Biochem 20: 687-702
53) A. Frey, A. Lampert, R. Möhle, J. Gallinat, F. Lang, U.E. Lang. Thyrotropin serum concentrations in
healthy volunteers are associated with depression-related personality traits. Neuropsychobiology (in
press)